FRAT2 Antikörper (AA 131-230) (Cy7)

Produktnummer ABIN1708429

Produktdetails anti-FRAT2 Antikörper (Cy7)

Target: FRAT2 (Frequently Rearranged in Advanced T-Cell Lymphomas 2 (FRAT2))

Bindungsspezifität: AA 131-230

Reaktivität: Maus

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser FRAT2 Antikörper ist konjugiert mit Cy7

Applikation: Western Blotting (WB), Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p))

Kreuzreaktivität: Maus

Homologie: Human,Rat,Dog,Cow,Sheep

Aufreinigung: Purified by Protein A.

Immunogen: KLH conjugated synthetic peptide derived from human FRAT2

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Lagerung: -20 °C

Informationen zur Lagerung: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Haltbarkeit: 12 months

Details zu FRAT2

Target: FRAT2 (Frequently Rearranged in Advanced T-Cell Lymphomas 2 (FRAT2))

Andere Bezeichnung: FRAT2 (FRAT2 Produkte)

Synonyme: FRAT2 antikoerper, FRAT2, WNT signaling pathway regulator antikoerper, frequently rearranged in advanced T cell lymphomas 2 antikoerper, frequently rearranged in advanced T-cell lymphomas 2 antikoerper, FRAT2 antikoerper, Frat2 antikoerper

Hintergrund:

Synonyms: Frequently rearranged in advanced T-cell lymphomas 2 antibodyGSK-3 binding protein FRAT2, FRAT2_HUMAN.

Background: FRAT1 and FRAT2 were originally characterized as proteins frequently rearranged in advanced T cell lymphoma, and they have since been identified as proto-oncogenes involved in tumorigenesis. These proteins share significant homology with the Xenopus glycogen synthase kinase-3 (xGSK-3) binding protein, which is designated GBP and is essential for the formation of the dorsal-ventral axis during embryonic development. Establishment of these embryonic axes is mediated by the Wnt intracellular signaling pathway. Wnt signaling is regulated in part by the activity of GSK-3, which phosphorylates and thereby facilitates the degradation of ?catenin. GBP binds to GSK-3 and inhibits this phosphorylation, resulting in the accumulation of ?catenin and the subsequent transcription of Wnt target genes. Like GBP, FRAT2 has been shown to bind xGSK-3, suggesting that FRAT1 and FRAT2 may be GSK-3 regulatory proteins.

Gen-ID: 23401